Kriya Therapeutics Names Greg Di Russo, MD, As Chief Medical Officer To Lead Clinical Strategy, Medical Affairs, And Drug Safety Across Its Growing Gene Therapy Pipeline

Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for diseases that affect millions of people worldwide, announced the appointment of Greg Di Russo, MD, as its new Chief Medical Officer. In this position, Dr. Di Russo will lead the company’s medical organization, which includes clinical development strategy and execution, medical affairs, and drug safety. His leadership will support Kriya’s ongoing efforts to advance multiple gene therapy programs through clinical development.

Shankar Ramaswamy, MD, Co-Founder and CEO of Kriya, said that Dr. Di Russo brings strong leadership and a proven history of advancing complex therapies across several therapeutic areas. He added that Kriya looks forward to Dr. Di Russo’s guidance as the company continues to grow and works toward addressing chronic diseases with significant unmet medical needs, with the broader goal of establishing gene therapy as a mainstream treatment option.

Dr. Di Russo has more than twenty years of experience spanning clinical practice and the pharmaceutical industry. His background includes early- and late-stage development of gene therapies, biologics, and small-molecule medicines for both adult and pediatric diseases. In his statement, Dr. Di Russo expressed enthusiasm about joining Kriya during a period when gene therapy is poised to make a substantial impact for patients with serious conditions. He noted that the company’s scientific capabilities and its commitment to a collaborative, patient-centered approach create a strong foundation for delivering innovative treatments.

Before joining Kriya, Dr. Di Russo served as Development Head for Non-Malignant Hematology at Pfizer, where he led the development of the company’s hemophilia and sickle cell disease portfolios. His responsibilities included oversight of the gene therapies BEQVEZ and giroctocogene fitelparvovec, as well as several global regulatory submissions. Prior to his role at Pfizer, he held positions at CSL Behring and Bristol-Myers Squibb. Earlier in his career, he practiced congenital cardiothoracic surgery at the University of Utah and Children’s National Hospital in Washington, D.C. Dr. Di Russo earned his medical degree from Sidney Kimmel Medical College and his undergraduate degree from Princeton University.